Aclaris falls after mid-stage trial setback for dermatitis drug

Aclaris Therapeutics

10/01/2024 12:40

** Shares of Aclaris Therapeutics  ACRS.O  fall ~10% to
$1.15 premarket
    ** Co says the once-daily version of its atopic dermatitis
drug did not show statistical significance in a mid-stage trial
    ** Adds, the twice daily version met the trial's main goal
    ** Atopic dermatitis causes itching, leading to skin
reddening, swelling and cracking 
    ** Stock fell 93.3% in 2023

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))